RCS - Redx Pharma plc - Preclinical Data on RXC008 Presented at UEG Week

AstraZenecaAnnouncement

14/10/2024 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241014:nRSN1026Ia&default-theme=true

RNS Number : 1026I  Redx Pharma plc  14 October 2024

 

 

REDX PHARMA LIMITED

("Redx" or the "Company")

 

Redx Presents Preclinical Data on RXC008, a Potential First-in-Class Therapy
to Treat Fibrostenotic Crohn's Disease, at the UEG Week

Presentation submission wins Top Abstract Prize

The oral presentation, entitled "RXC008: First-in-Class
Gastrointestinal-Targeted Potent Pan-ROCK Inhibitor for Treatment of
Fibrostenotic Crohn's Disease", was  delivered on Monday 14 October, during
the session: IBD: New horizons in medical treatment - Part 1

RXC008 is currently in phase 1 clinical development where results from healthy
volunteer cohorts are expected to be available by the end of 2024

Alderley Park, UK, 14 October 2024 Redx Pharma (https://www.redxpharma.com/)
(JPJ:REDX), the clinical-stage, small molecule biotechnology company, today
presents on RXC008, at the United European Gastroenterology (UEG) Week
Congress, October 12-15, Vienna, Austria.

RXC008 is a gastrointestinal (GI)-restricted highly potent and selective
pan-ROCK inhibitor, currently in phase 1 clinical development to treat
fibrostenotic Crohn's disease, where results from healthy volunteer cohorts
are expected to be available before year end.

The presented preclinical results included data demonstrating RXC008's strong
anti-fibrotic therapeutic effects in animal models of inflammatory bowel
disease and confirms the cardiovascular safety profile of a GI-restricted
pan-ROCK inhibitor through animal toxicology studies.

Dr Elaine Kilgour, Head of Translational Science, Redx, and lead author of the
abstract, has been awarded a UEG Top Abstract Prize, one of five awarded to
the first author of abstracts submitted to this year's Congress. Abstracts are
eligible for this prize if they have not been previously presented at an
international meeting. UEG Week is the largest annual GI-focussed congress in
Europe. It features the latest advances in clinical management and research in
the field of digestive and liver disease. UEG is the leading non-profit
organisation for excellence in digestive health in Europe. Their mission is to
improve the prevention and care of digestive diseases through providing top
tier education, supporting research and advancing clinical standards.

Dr Elaine Kilgour, Head of Translational Science, Redx, and lead author of the
abstract, said: "We are excited to be developing a novel compound for the
debilitating indication of fibrostenotic Crohn's disease. RXC008 has
demonstrated encouraging findings in preclinical studies. Its marked
antifibrotic effect, yet GI-restriction bodes well for its potential in the
clinic."

Dr Helen Timmis, Interim Chief Medical Officer at Redx added: "RXC008 holds
great promise as a novel treatment for fibrostenotic Crohn's disease. There
are currently no approved therapies for treating underlying progressive
fibrosis of the intestine which leads to stricturing and penetrating disease.
Anti-inflammatories suppress inflammation but do not treat the underlying
fibrosis, leaving patients with invasive surgical interventions as their only
therapeutic option".

Rho-associated coiled-coil forming protein kinase (ROCK) is well established
as an anti-fibrotic target and is known to consist of two isoforms ROCK 1 and
2.  RXC008 is a potent, oral, small molecule non-systemic ROCK 1/2 inhibitor
that avoids the significant cardiovascular side effects of systemic pan-ROCK
inhibitors, including tachycardia and hypotension, by being restricted to the
GI-tract via high efflux and low permeability. This results in virtually no
systemic breakthrough, with the molecule being rapidly metabolised by
paraoxonase enzymes in the plasma should any breakthrough occur under
particular circumstances.

Crohn's disease affects 1.7m i  (#_edn1) people globally and >70,000 new
cases are diagnosed each year. More than 50% of patients ii  (#_edn2) with
Crohn's disease can develop significant fibrosis and stricture formation
within ten years after diagnosis; this fibrosis associated with Crohn's
disease is known as fibrostenotic Crohn's disease. The current management of
fibrotic strictures of the gastrointestinal tract is primarily surgical as no
drugs are specifically approved for fibrosis, which can progress despite
intervention with anti-inflammatory therapies.

 Oral Presentation Details:

 Title: RXC008: First-in-Class Gastrointestinal-Targeted Potent Pan-ROCK
 Inhibitor for Treatment of Fibrostenotic Crohn's Disease

 Session: IBD: New horizons in medical treatment - Part 1

 Day/Date: Monday 14 October 2024

 Presentation Time: 10:00-10:12 CEST

 Location: Messe Wien Exhibition & Congress Center, Messe Wien, Entrance A,
 Messeplatz 1, 1020 Vienna, Austria

 A copy of the abstract presentation deck will be made available on the
Company website at: https://www.redxpharma.com/scientific-publications.

 

 For further information, please contact:

 Redx Pharma Limited                            T: +44 (0)1625 469 918

 Erin Hamid, Interim Head of Communications

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 FTI Consulting                                 T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

 

 

About Redx Pharma Limited

Redx Pharma (JPJ: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, targeted therapeutics
for the treatment of fibrotic disease, cancer and the emerging area of
cancer-associated fibrosis. Redx aims to progress its programmes to clinical
proof of concept before evaluating options for further development and
potential value creation. The Company is currently progressing an industry
leading ROCK inhibitor portfolio through the clinic, including zelasudil, a
selective ROCK2 inhibitor for the treatment of interstitial lung diseases
including idiopathic pulmonary fibrosis and RXC008, a GI-targeted pan-ROCK
inhibitor for the treatment of fibrostenotic Crohn's disease.  Additionally,
the Company has a Phase 2 precision oncology programme which it intends to
partner for further development.

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. To date, six Redx
discovered molecules have been progressed into the clinic with the Company's
accomplishments evidenced not only by its wholly-owned clinical-stage product
candidates and discovery pipeline, but also by its strategic transactions,
which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only
non-covalent or reversible BTK inhibitor now approved by the US FDA, and
transactions with both AstraZeneca and Jazz Pharmaceuticals.

 

 i  (#_ednref1) Clarivate, Crohn's disease landscape & forecast p.g. 39,
Published Sep 2022

 ii  (#_ednref2) Chan et al, 2018

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFSFELELSEDS